Tumor Angiogenesis as a Target for Dietary Cancer Prevention
Table 4
Approved antiangiogenic agents and cancer indications.
Bevacizumab (Genentech/Roche)
Colon, Lung, Breast, Brain, Kidney
Cetuximab (Bristol-Myers Squibb/Imclone)
Colon, Head and Neck
Endostatin (Simcere)†
Lung
Erlotinib (Genentech/Roche/OSI)
Lung, Pancreatic
Everolimus (Novartis)
Kidney, Pancreatic/NET*, Brain/SEGA**
Imiquimod (Graceway/3M)
Actinic keratosis, Basal cell carcinoma
Interferon alfa (Roche/Schering)
Melanoma, Kaposi's sarcoma
Lenalidomide (Celgene)
Myleodysplastic syndrome, Multiple myeloma
Pazopanib (GlaxoSmithKline)
Kidney
Sorafenib (Bayer/Onyx)
Kidney, Liver
Sunitinib (Pfizer)
Kidney, GIST, Pancreatic/NET*
Temsirolimus (Wyeth)
Kidney, Lymphoma
Thalidomide (Celgene)
Multiple myeloma
Vandetanib (AstraZeneca)
Thyroid
†Available only in China.
*
Neuroendocrine tumor.
**
Subependymal giant cell astrocytoma, associated with tuberous sclerosis. Source: Angiotracker, The Angiogenesis Foundation (http://www.angio.org/).
